On a recent Sunday night, more than 100 people squeezed into a Twin Peaks mansion for an invite-only meetup called the California Peptide Club, where founders, clinicians and biohackers compared vials, traded dosing tips and watched a volunteer mix and inject a buzzy weight-loss peptide. The vibe landed somewhere between tech salon and pop-up clinic: insulin syringes on tables, a peptide “starter kit” raffle and a thicket of phones aimed at the live injection demo.
According to Business Insider, the AGI House event on Twin Peaks drew more than 100 attendees, left roughly 300 people stuck on the waitlist and is something organizer Julius Ritter hopes to turn into a monthly ritual. The closed-door gathering featured panels, a peptide fridge quiz and a speaker lineup that ranged from prescribing clinicians to a peptide manufacturer and a Stanford researcher. The pitch: a place to compare stacks and trade what organizers framed as real-world, in-the-trenches protocols.
"My roommates made fun of me," Ritter told Business Insider, explaining how the club began. He said the aim was to drag scattered peptide chatter out of message boards and Discord threads and into a room where clinicians, manufacturers and curious tech workers could hash things out face-to-face. Even so, many attendees acknowledged they were using products labeled research use only, a designation that brings a tangle of legal and safety questions along with it.
Those risks are not hypothetical. Reporting and public records show that peptide injections at other longevity-themed events have gone badly wrong: ProPublica found that two people who received peptide injections at a Las Vegas festival ended up hospitalized on ventilators, and a Southern Nevada Health District memo also logs acute illnesses tied to that same event. The U.S. Food and Drug Administration warns that several popular peptides may present significant safety risks because of issues such as immunogenicity, impurities, and limited human-safety data, and the agency has placed many of those compounds on its bulk list for compounding review.
Policy Signal, Not A Rule Change
Federal officials have hinted they want to loosen access to at least some peptides, but analysts stress that public hints are not the same thing as binding rules. Legal and industry commentary notes that the HHS secretary has publicly voiced an intent to reclassify a subset of restricted peptides, yet formal FDA rulemaking or an updated bulk list, the step that would actually reopen compounding for many of these substances, had not been published as of mid-April. The law firm Frier Levitt walks through that regulatory process and emphasizes that the announcement amounts to policy signaling rather than a completed regulatory change.
Why Silicon Valley Is Hooked
Locally, the draw is as cultural as it is chemical. Founders here talk about productivity, recovery and cognitive edge the way they talk about runway and valuations, and the event’s promotional language leaned hard on new clinical trial results and market buzz. The club’s public listing and agenda spotlight compounds such as retatrutide and promise sessions on testing, compounding and startup opportunities in the peptide world, while AGI House markets itself as a hangout where founders and researchers swap cutting-edge ideas. That cocktail of hype, peer pressure and one-click access to research-grade vials goes a long way toward explaining why the room filled so fast.
What Experts Say
Public-health officials and compliance experts point to two big hazards: opaque supply chains and injections happening outside proper medical settings. The FDA’s documentation on bulk drug substances outlines specific safety concerns for several peptides, and the Nevada investigation into the Las Vegas festival remains a stark reminder that injections given away from licensed clinical infrastructure can cause sudden, life-threatening complications. For people curious about peptide therapy, physicians and legal analysts advise sticking with licensed prescribers and regulated suppliers instead of ordering "research-use" vials and trying to manage injections on their own.
